- Brand name:
- Pharmaceutical Company:
- Condition/Indication: Nausea and vomiting associated with cytotoxic chemotherapy
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Ondansetron – March 2020
Ondansetron: Wafer 4 mg, 8 mg; Tablet (as hydrochloride dehydrate) 4 mg, 8 mg; Tablet (orally disintegrating) 4 mg, 8 mg; various brands
Last updated
9 July 2025